- Home
- HOUR vs AARD Comparison
HOUR vs AARD Comparison
Compare HOUR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOUR | AARD |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.4M | 85.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HOUR | AARD |
|---|---|---|
| Price | $2.40 | $6.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | ★ 142.2K | 127.6K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $142,440,236.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.40 | ★ N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $1.18 | $3.35 |
| 52 Week High | $6.84 | $17.94 |
Technical Indicators
Market Signals| Indicator | HOUR | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 59.59 |
| Support Level | $1.80 | $4.81 |
| Resistance Level | $2.61 | $11.37 |
| Average True Range (ATR) | 0.30 | 0.40 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 40.46 | 90.70 |
Price Performance
Historical ComparisonAbout HOUR Hour Loop Inc.
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.